Please login to the form below

Not currently logged in
Email:
Password:

J&J to aquire Cougar

Johnson & Johnson has filed a tender offer statement with the Securities and Exchange Commission to purchase all outstanding shares

Johnson & Johnson has filed a tender offer statement with the Securities and Exchange Commission (SEC) to purchase all outstanding shares in Cougar Biotechnology. It reported its intent to acquire the Los Angeles-based biotech company in May this year.

Courgar's board of directors has unanimously approved the merger and, if the deal closes successfully, shareholders will receive $43 per share. The company in-licenses and develops clinical stage oncology drugs and currently has products in trials for prostate cancer, breast cancer, multiple myeloma and solid tumours.

The transaction is expected to close during the third quarter of 2009 and is subject to various conditions.

8th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics